Patents Issued in June 7, 2018
-
Publication number: 20180153783Abstract: Suggested is a cosmetic composition comprising an anti-pollution agent selected from the group consisting of E/Z-2-benzylindene-5,6-dimethoxy-3,3-dimethylindan-1-one, sclareolide, purple coneflower pressed juice, ginger root CO2 extract or mixtures thereof, in a working amount sufficient for (a) reducing or preventing air pollution induced gene expression, and/or (b) reducing or preventing a gene expression induced or inducible by polycyclic aromatic hydrocarbons, and/or (c) reducing or preventing air pollution-induced or air pollution-inducible skin damage.Type: ApplicationFiled: May 24, 2016Publication date: June 7, 2018Inventors: Jean Krutmann, Imke Meyer, William Johncock, Gerhard Schmaus, Marielle le Maire, Martina Herrmann
-
Publication number: 20180153784Abstract: The invention relates to a cosmetic composition comprising, in a physiologically acceptable aqueous medium, a jasmonic acid compound and a non-ionic associative polyurethane/polyether polymer. Use for caring for and making up keratin materials.Type: ApplicationFiled: December 2, 2016Publication date: June 7, 2018Inventors: Cecile Kermorvan, Magali Szestak
-
Publication number: 20180153785Abstract: The present invention is directed towards the cosmetic use of at least one compound of formula (I) and/or solvates thereof and/or stereoisomers thereof: in which groups A and B are different and: A-* represents a disubstituted phenyl radical: B-** represents a mono- or disubstituted phenyl radical: or of a composition comprising, in a physiologically acceptable medium, at least one compound of formula (I), for treating and/or preventing the signs of ageing and/or of photoageing of keratin materials, preferably of the skin.Type: ApplicationFiled: May 27, 2016Publication date: June 7, 2018Inventor: Julien HITCE
-
Publication number: 20180153786Abstract: Provided are largely aqueous topical antimicrobial cleaning composition which provides an antimicrobial benefit, as well as methods for their production and methods for their use. The compositions comprise at least two different cationic surfactants which provide a primary antimicrobial benefit, and as a predominant further surfactant an amine oxide surfactant. The composition are at an acidic pH and are highly effective in providing an antimicrobial benefit to topical surfaces, e.g, epidermis and hair.Type: ApplicationFiled: December 20, 2017Publication date: June 7, 2018Inventor: Sarah De Szalay
-
Publication number: 20180153787Abstract: Embodiments of the present invention are directed to methods and articles of manufacture to treat skin to improve and/or increase hydration, pliability, and thickness for improved texture, feel and appearance. Embodiments feature applying an effective amount of an acetylation agent to natural dermal collagen under reaction conditions to react the natural dermal collagen with the acetylation agent to form a modified collagen. The modified collagen has a higher net charge and higher net charge density than natural dermal collagen. The modified collagen improves or increases one or more skin characteristics consisting of hydration, pliability and thickness.Type: ApplicationFiled: November 21, 2017Publication date: June 7, 2018Inventors: Leonard B. Miller, Dale P. Devore
-
Publication number: 20180153788Abstract: Described herein is a method of dyeing the hair. The method includes applying to the hair a hair color composition including one or more direct dye compounds and rinsing the hair with water. The one or more direct dye compounds each include a chromophore, one or two permanent cations, and one to four incipient cations. The one to four incipient cations are pendant to the core structure and are neutral. The one or more direct dye compounds enter the hair shaft after the hair color composition is applied to the hair. The hair color composition has a pH of from about 7 to about 11. The pH of the hair after rinsing is from about 3.5 to about 6. The rinsing of the hair causes one or more of the one to four incipient cations to change from neutral to positively charged inside of the hair shaft.Type: ApplicationFiled: November 21, 2017Publication date: June 7, 2018Inventors: Guiru Zhang, Bryan Patrick Murphy, Peter Marte Torgerson
-
Publication number: 20180153789Abstract: The present disclosure related to an oral composition, and more particularly, to an oral composition for reducing tooth sensitivity. More specifically, the oral composition contains zinc and a copper salt capable of occluding dental tubules by agglomerating proteins, contributing to the reduction effect of tooth sensitivity, and to maintain this, allows a water soluble or alcohol soluble polymer to coat the dental tubules and be maintained for a long time, thereby solving the main cause of tooth sensitivity, as a result, providing an effect on the prevention or reduction of symptoms of tooth sensitivity in a short time.Type: ApplicationFiled: April 15, 2016Publication date: June 7, 2018Applicant: LG HOUSEHOLD & HEALTH CARE LTD.Inventors: So-Eun GIM, Kyo-Tae MOON, Won-Ho HA, Jae-Hyun AHN, In-Ho LEE
-
Publication number: 20180153790Abstract: Disclosed are hair styling compositions comprising at least two latex polymers chosen from acrylate and polyurethane polymers, wherein at least one latex polymer is a film-forming polymer. Methods of styling the hair are also disclosed.Type: ApplicationFiled: November 7, 2017Publication date: June 7, 2018Inventors: Siliu TAN, Nghi Van NGUYEN, Jim SINGER, Jean-Thierry SIMONNET
-
Publication number: 20180153791Abstract: Applications of low-viscosity phenyl trimethicones in cosmetic and personal care products, cosmetic and personal care formulas containing low-viscosity phenyl trimethicones with various improved properties over use Phenyl Trimethicone @ 20 cSt or @ 40 cSt, and preparation methods thereof are disclosed.Type: ApplicationFiled: April 29, 2016Publication date: June 7, 2018Inventors: Stacey House, Catherine Mercado, Deborah McCarthy, David Schlossman
-
Publication number: 20180153792Abstract: The invention relates to a photo-protective personal care composition, especially to one that provides enhanced stability of a UVA sunscreen of the dibenzoylmethane class when a UVB sunscreen of the cinnamic acid class is also present. This has been achieved by entrapping the UVA sunscreen in a matrix comprising a specific silica and a specific silicone and combining this with a UVB sunscreen being entrapped in a gel made of a silicone elastomer and a volatile silicone.Type: ApplicationFiled: May 20, 2016Publication date: June 7, 2018Applicant: Conopco, Inc., d/b/a UNILEVERInventors: Anjing LOU, Teanoosh MOADDEL, Wenhui SONG, Wei ZHAO
-
Publication number: 20180153793Abstract: A cosmetic composition includes: (i) one or more vegetable butters in an amount of from 5 to 35% by weight of the total composition; (ii) one or more vegetable oils in an amount of from 20 to 50% by weight of the total composition; and (iii) starch in an amount of from 40 to 85% by weight of the total composition. The cosmetic composition is free from preservatives as defined herein.Type: ApplicationFiled: April 21, 2016Publication date: June 7, 2018Applicant: Cosmetic Warriors LimitedInventors: Mark CONSTANTINE, Margaret Joan CONSTANTINE, Helen Elizabeth AMBROSEN, Rowena Jacqueline BIRD
-
Publication number: 20180153794Abstract: Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed.Type: ApplicationFiled: November 17, 2015Publication date: June 7, 2018Inventors: Vladimir Coric, Robert Berman, Ronald S. Vladyka, Amgad Saleh, Danny Yu
-
Publication number: 20180153795Abstract: The invention provides liquid formulations containing buprenorphine, a pharmaceutically acceptable salt thereof, or a derivative thereof. The invention further provides liquid formulations containing buprenorphine and naloxone, pharmaceutically acceptable salts thereof or derivatives thereof. The invention further provides a method of treating pain or opioid dependence by administering liquid formulations containing buprenorphine or a combination of buprenorphine and naloxone, a pharmaceutically acceptable salt thereof, or a derivative thereof to a patient in need thereof.Type: ApplicationFiled: February 2, 2018Publication date: June 7, 2018Inventors: Kiran P. Amancha, Chandeshwari S. Chilampalli, Venkat R. Goskonda
-
Publication number: 20180153796Abstract: Metal-organic frameworks (MOFs) comprising photosensitizers are described. The MOFs can also include moieties capable of absorbing X-rays or other ionizing irradiation energy and/or scintillation. Optionally, the photosensitizer or a derivative thereof can form a bridging ligand of the MOF. Further optionally, the MOF can comprise inorganic nanoparticles in the cavities or channels of the MOF or can be used in combination with an inorganic nanoparticle. Also described are methods of using MOFs and/or inorganic nanoparticles in photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, or in radiotherapy-radiodynamic therapy, either with or without the co-administration of one or more immunotherapeutic agent and/or one or more chemotherapeutic agent.Type: ApplicationFiled: January 30, 2018Publication date: June 7, 2018Inventors: Wenbin Lin, Chunbai He, Kuangda Lu, Kaiyuan Ni, Guangxu Lan
-
Publication number: 20180153797Abstract: The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration.Type: ApplicationFiled: July 24, 2017Publication date: June 7, 2018Inventors: James CLOYD, Angela BIRNBAUM, Ilo LEPPIK, Stephen D. COLLINS
-
Publication number: 20180153798Abstract: There is provided glucagon formulations suitable for preparing coatings on microneedle patches for the transdermal delivery of glucagon. The coated patches may be used for the treatment of low blood sugar in diabetic patients. Also provided are glucagon loaded patches, methods for their preparation, and methods of their use.Type: ApplicationFiled: October 9, 2017Publication date: June 7, 2018Inventors: Mahmoud Ameri, Peter E. Daddona, Yi Ao
-
Publication number: 20180153799Abstract: Compositions, devices and methods employing therapeutic concentrations of a triptan for treatment of migraine are described. Also described are methods and apparatuses for delivery of zolmitriptan for achieving a Tmax as quick as 2 minutes and not later than 30 minutes in the majority of subjects.Type: ApplicationFiled: January 29, 2018Publication date: June 7, 2018Inventors: Mahmoud Ameri, Donald Kellerman, Peter E. Daddona, Yi Ao
-
Publication number: 20180153800Abstract: The present disclosure provides lubricant compositions suitable for use on human tissue and effective to provide multiple sensations sequentially and/or in varying intensities. The lubricants can include a lubricating base and at least two different sensorial agents effective to impart different sensations, such as warming, cooling, tingling, refreshing, and numbing. The lubricants particularly can be suitable for use in sexual experiences so that the imparted sensations can increase and/or improve such experiences. The present disclosure further provides condoms incorporating such lubricant compositions.Type: ApplicationFiled: December 6, 2017Publication date: June 7, 2018Applicant: Church & Dwight Co. Inc.Inventors: Elisabeth Memin, Albert Nazareth, Kirsten Cluver, Caihua Wang, Melis Cakirer, Jason Kieke
-
Publication number: 20180153801Abstract: The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit containing at least 100 ?g of an estetrol component selected from estetrol, estetrol esters and combinations thereof; wherein the solid dosage unit can be obtained by a process comprising: ?providing an aqueous liquid comprising water, estetrol component and optionally one or more other pharmaceutically acceptable ingredients; ?mixing 1 part by weight of the aqueous liquid with 0.5-20 parts by weight of the carrier particles to produce wet particles; ?removing water from the wet particles to produce loaded particles; ?optionally mixing the loaded particles with one or more tabletting excipients; and ?forming the loaded particles or the mixture of loaded particles and the one or more tabletting excipients into a solid dosage unit. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.Type: ApplicationFiled: June 20, 2016Publication date: June 7, 2018Applicant: Mithra Pharmaceuticals S.A.Inventors: Séverine Francine Isabelle JASPART, Johannes Jan PLATTEEUW, Denny Johan Marijn VAN DEN HEUVEL
-
Publication number: 20180153802Abstract: The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.Type: ApplicationFiled: November 17, 2017Publication date: June 7, 2018Inventors: Stephen Perrett, Fredric Jay Cohen, Gopi Venkatesh
-
Publication number: 20180153803Abstract: Methods of delivering cromolyn to a patient in need thereof, methods of treating amyloid-associated conditions and inflammatory or allergic lung diseases, and packs and kits comprising cromolyn are described.Type: ApplicationFiled: December 4, 2017Publication date: June 7, 2018Applicant: AZTHERAPIES, INCInventor: David R. ELMALEH
-
FOAMABLE VEHICLES AND PHARMACEUTICAL COMPOSITIONS COMPRISING APROTIC POLAR SOLVENTS AND USES THEREOF
Publication number: 20180153804Abstract: The present invention teaches a foamable pharmaceutical and cosmetic compositions comprising an aprotic polar solvent; foam compositions and uses thereof.Type: ApplicationFiled: January 30, 2018Publication date: June 7, 2018Inventors: Dov Tamarkin, David Schuz, Tal Berman, Yohan Hazot -
Publication number: 20180153805Abstract: Disclosed herein are various compositions comprising neoplastic formulations and their methods of use.Type: ApplicationFiled: July 22, 2016Publication date: June 7, 2018Inventors: William T. Monte, Robert Malcolm Abra, Bing Luo, Yuanpeng Zhang
-
Publication number: 20180153806Abstract: Docetaxel and doxorubicin can be formulated in liposomal pharmaceutical compositions. In various embodiments, the pharmaceutical compositions include (i) a first liposome type comprising a first lipid layer comprising an unsaturated phospholipid, cholesterol or a cholesterol derivative, DC-cholesterol, a cationic lipid, and preferably a pegylated phospholipid, and a first active pharmaceutical ingredient (API) comprising docetaxel in the first lipid layer; and (ii) a second liposome type comprising a second lipid layer, an aqueous interior, and a second API comprising doxorubicin crystallized in the aqueous interior, (iii) where the first liposome type does not comprise doxorubicin and the second liposome type does not comprise docetaxel. The pharmaceutical composition can be used to treat a subject, for example, a human subject having cancer.Type: ApplicationFiled: January 17, 2018Publication date: June 7, 2018Inventors: De-Min Zhu, Guoqiang Chen
-
Publication number: 20180153807Abstract: Disclosed are methods of treating mycobacteria infections, such as nontuberculosis mycobacterial (NTM) lung disease and pulmonary tuberculosis, including refractory lung disease, by orally administering encochleated antibiotics, including aminoglycosides, such as amikacin. Orally administered antibiotic cochleates have significantly reduced toxicity as compared to intravenously administered antibiotics.Type: ApplicationFiled: April 22, 2016Publication date: June 7, 2018Inventor: Ruying Lu
-
Publication number: 20180153808Abstract: The present invention relates to vaccine compositions based on Gram-negative outer membrane vesicles displaying antigens of pathogens expressed as part of a fusion protein comprising N-terminal parts of surface expressed lipoproteins of Gram-negative bacteria, and use of such compositions in vaccination. The invention further relates to the fusion lipoproteins comprising N-terminal parts of surface expressed lipoproteins of Gram-negative bacteria and antigens of pathogens fused thereto, DNA constructs and bacterial host cells for expressing these fusion lipoproteins and to methods for producing outer membrane vesicles displaying the fusion lipoproteins.Type: ApplicationFiled: June 2, 2016Publication date: June 7, 2018Applicant: De Staat der Nederlanden, vert door de minster van VWS, Ministerie van Volksgezondheid, Welzijn en SInventors: Merijn Louis Marten SALVERDA, Peter André VAN DER LEY
-
Publication number: 20180153809Abstract: Provided is a powder composition containing an oily substance, the powder composition having good oxidation stability and excellent compression moldability. The powder composition containing an oily substance contains a powdery calcium silicate-based material, and an oily substance impregnated into the material. In the material, a cumulative pore volume for a pore size of 10 to 70 nm is 1.1 cc/g or more, and a cumulative pore volume for a pore size of 70 to 500 nm is 2.0 cc/g or less.Type: ApplicationFiled: May 27, 2016Publication date: June 7, 2018Inventors: TAKANORI TANIWAKI, KAZUKI KAMAI, YUUTA TSUMURA, DAICHI MASAKI
-
Publication number: 20180153810Abstract: Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.Type: ApplicationFiled: July 12, 2017Publication date: June 7, 2018Inventors: Paul F. GLIDDEN, Alison J. PILGRIM, Stephen R. HANSON
-
Publication number: 20180153811Abstract: The present invention is directed to a method of preparing dehydrated blood products, comprising the steps of: (a) providing a hydrated blood product; (b) spray-drying the hydrated blood product to produce a dehydrated blood product, as well as dehydrated blood products made by the method. The present invention is directed to a method of treating a patient suffering from a blood-related disorder, comprising the steps of: (a) rehydrating a therapeutic amount of the dehydrated blood products to produce a rehydrated therapeutic composition; and (b) administering the rehydrated therapeutic composition to the patient. The present invention is directed to a bandage or surgical aid comprising the dehydrated blood products described above.Type: ApplicationFiled: January 16, 2018Publication date: June 7, 2018Applicant: Entegrion, Inc.Inventors: Thomas H. Fischer, Joseph A. DaCorta, Michael Lawrence Galiger
-
Publication number: 20180153812Abstract: Opioid controlled release formulation resistant to alcohol extraction of the opioid.Type: ApplicationFiled: February 1, 2018Publication date: June 7, 2018Inventors: Richard O. Mannion, William H. Mckenna, Edward P. O'donnell, Helen Kathleen Danagher, Geoffrey Gerard Hayes, Hassan Mohammad, Derek Allan Prater, Harjit Tamber, Malcolm Walden, Steve Whitelock, Wolfgang Fleischer, Udo Hahn, Christof Spitzley, Christian Leuner
-
Publication number: 20180153813Abstract: The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.Type: ApplicationFiled: January 31, 2018Publication date: June 7, 2018Inventors: Alex Nivorozhkin, Nelson Landrau
-
Publication number: 20180153814Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: ApplicationFiled: January 31, 2018Publication date: June 7, 2018Applicants: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.Inventors: William H. MCKENNA, Richard O. MANNION, Edward P. O'DONNELL, Haiyong H. HUANG
-
Publication number: 20180153815Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: ApplicationFiled: January 31, 2018Publication date: June 7, 2018Applicants: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.Inventors: William H. MCKENNA, Richard O. MANNION, Edward P. O'DONNELL, Haiyong H. HUANG
-
Publication number: 20180153816Abstract: Embodiments of the invention provide drug packaging and methods for producing drug packaging which can be sealed at room temperature and/or without the need for elevated temperatures above room temperature. Many embodiments provide drug packaging comprising pierceable tubing having a capsule shape (also referred to herein as a pierceable capsule and/or pierceable drug capsule) containing a solid drug such as a drug pellet and methods for producing pierceable drug capsules which can be sealed at room temperature. Embodiments are particularly useful for the packaging and delivery of drugs used in implantable drug delivery devices as well as packaging of drugs that are easily thermally degraded.Type: ApplicationFiled: January 30, 2018Publication date: June 7, 2018Inventors: Elmar Fischer, Paul Spehr
-
Publication number: 20180153817Abstract: A composition is described having improved oral permeability of polar agents such as neuraminidase inhibitors. The composition includes one or more polar agents and one or more permeability enhancers such that the composition increases the amount of the polar agent capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 Cell membrane in the absence of the permeability enhancer. Oral dosage forms including the composition, and methods of treating or preventing influenza infection are also provided.Type: ApplicationFiled: October 6, 2017Publication date: June 7, 2018Applicant: ALA WAI PHARMA, INC.Inventors: Eric Holmes, Michael Hite
-
Publication number: 20180153818Abstract: Phospholipid-coated nanoparticles containing a therapeutic agent, compositions that include the nanoparticles, and methods for making and using the nanoparticles and compositions.Type: ApplicationFiled: September 14, 2017Publication date: June 7, 2018Applicant: Autotelic LLCInventors: Vuong Trieu, Tapas K. De
-
Publication number: 20180153819Abstract: An object is to provide a technology that relates to a protein nanocapsule capable of holding a substance to be encapsulated such as a drug and in which the protein nanocapsule can be introduced into a cell using a simple method and the encapsulated substance can reach a target in a cell. The present invention relates to a nanocapsule for a drug delivery system including, as a carrier material for encapsulation of a pharmacological component for a nanocapsule for a system of local drug delivery into a cell, a mutant chaperonin complex including an ATP hydrolysis activity-lowered GroEL subunit mutant as a GroEL subunit included in a ring structure and a subunit having GroES activity as a subunit included in an apex portion.Type: ApplicationFiled: May 11, 2016Publication date: June 7, 2018Inventors: Ayumi Koike, Hiromi Yoda, Takeji Takamura
-
Publication number: 20180153820Abstract: Provided herein are methods for the treatment of metastatic pancreatic cancer comprising administration of a composition comprising nanoparticles comprising a taxane (such as paclitaxel) and a carrier protein in combination with gemcitabine.Type: ApplicationFiled: November 21, 2017Publication date: June 7, 2018Inventors: Neil P. Desai, Markus Renschler
-
Publication number: 20180153821Abstract: The present invention relates to prevention and/or treatment of diseases or disorders associated with a damaged or leaky vasculature in a subject. The present invention provides for methods, combinations and pharmaceutical compositions for preventing and/or treating a disease or disorder associated with a damaged or leaky vasculature in a subject, using, inter alia, an effective amount of a nanoparticle comprising an inner core comprising a non-cellular material, an outer surface comprising a cellular membrane derived from a platelet; and optionally an agent for preventing, treating, diagnosing, or prognosing the disease or disorder and/or monitoring prevention or treatment of the disease or disorder. Exemplary diseases or disorders include hemorrhage (bleeding), cardiovascular diseases or disorders, diseases or disorders associated with narrowing of a blood vessel, tumors or cancers.Type: ApplicationFiled: June 7, 2016Publication date: June 7, 2018Inventors: Liangfang Zhang, Che-Ming Jack Hu, Ronnie H. Fang, Brian T. Luk, Kuei-Chun Wang, Shu Chien
-
Publication number: 20180153822Abstract: The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a solution of pre-formed lipid nanoparticles and mRNA.Type: ApplicationFiled: November 10, 2017Publication date: June 7, 2018Inventors: Shrirang Karve, Frank DeRosa, Zarna Bhavsar, Michael Heartlein
-
Publication number: 20180153823Abstract: A transdermal drug delivery composition comprises an acrylate copolymer and from about 8% to about 30% by weight fentanyl. A transdermal fentanyl delivery composition comprising methyl laurate or tetraglycol as a permeation enhancer is also provided. The transdermal drug delivery compositions can be used to make a transdermal drug delivery device for the delivery of fentanyl.Type: ApplicationFiled: January 26, 2018Publication date: June 7, 2018Inventors: Adam S. Cantor, Terrance W. Ocheltree, Cynthia A. Robles
-
Publication number: 20180153824Abstract: The invention provides pharmaceutical compositions and dosage forms of fluorocarbon nanoemulsions that are useful for treating sickle cell disease and related diseases and conditions, as well as methods of preparation and use thereof.Type: ApplicationFiled: May 27, 2016Publication date: June 7, 2018Inventors: Evan C. Unger, Solomon F. Ofori-Acquah, David B. Wilson
-
Publication number: 20180153825Abstract: A dihydroxyacetone fortified honey composition, including a mixture of honey and dissolved dihydroxyacetone in a preferred honey to dissolved dihydroxyacetone ratio of 0.5 ml-20 ml of dissolved dihydroxyacetone to each kilogram of honey, wherein the mixture has a moisture content of between one and twenty percent, and wherein the mixture contains a preferred amount of methylglyoxal of between 83 milligrams of methylglyoxal per 1.0 kilogram of honey and 1500 milligrams of methylglyoxal per 1.0 kilogram of honey.Type: ApplicationFiled: August 15, 2017Publication date: June 7, 2018Applicant: LINKS MEDICAL PRODUCTS INCORPORATEDInventors: Thomas L. Buckley, Andrew Thain
-
Publication number: 20180153826Abstract: In preferred embodiments, the invention pertains to the treatment of Cystic Fibrosis (CF) using an agonistic of CaSR. In a specific embodiment, the subject invention provides a method of treating CF in a subject by administering to the subject a composition comprising a calcimimetic. The calcimimetic can be administered alone or in combination with a CaSR orthosteric agonist and/or an agent capable of stimulating colonic HCO3? secretion in CFTR-independent manner. The composition can be administered to the subject via inhalation. Accordingly, the invention further pertains to compositions comprising a calcimimetic and optionally, further comprising a CaSR orthosteric agonist and/or an agent capable of stimulating colonic HCO3? secretion in CFTR-independent manner, in the form suitable for administration to the subject via inhalation. Accordingly, devices for administering the compositions of the current invention via inhalation are also provided.Type: ApplicationFiled: May 4, 2016Publication date: June 7, 2018Inventor: SAM XIANJUN CHENG
-
Publication number: 20180153827Abstract: Methods and compositions for use in treating, preventing or improving diseases related to the liver in an animal, including but not limited to nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD) or nonalcoholic steatohepatitis (NASH), are described. The compounds of the present invention are gamma-ketoaldehyde scavengers.Type: ApplicationFiled: September 6, 2017Publication date: June 7, 2018Inventors: John Rathmacher, Naji Abumrad, Charles Flynn
-
Publication number: 20180153828Abstract: Disclosed herein are methods of inhibiting tumor growth or producing tumor regression in a subject having a drug-resistant estrogen receptor alpha positive cancer or a mutant estrogen receptor alpha positive cancer. The methods entail administering to the subject a therapeutically effective amount of RAD1901 having the structure: or a salt or solvate thereof.Type: ApplicationFiled: October 26, 2017Publication date: June 7, 2018Inventors: Fiona GARNER, Gary HATTERSLEY
-
Publication number: 20180153829Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising cis-clomiphene or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: January 25, 2018Publication date: June 7, 2018Applicant: ASPEN PARK PHARMACEUTICALS, INC.Inventors: MITCHELL STEINER, Harry Fisch
-
Publication number: 20180153830Abstract: Uses of a compound of any of Formulas I-VI as a cytotoxic inhibitor of undifferentiated cells are disclosed herein, as well as pharmaceutical compositions comprising a compound of any of Formulas I-VI, and methods for identifying a lead candidate for inhibiting undifferentiated cells. Further disclosed are uses of an SCD-1 inhibitor as a cytotoxic inhibitor of undifferentiated cells.Type: ApplicationFiled: February 1, 2018Publication date: June 7, 2018Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Hoffmann-La Roche Inc.Inventors: Uri BEN-DAVID, Nissim BENVENISTY, Payal ARORA, Qing-Fen GAN, Ralph J. GARIPPA
-
Publication number: 20180153831Abstract: The invention provides novel compounds having the general formula I: wherein R1, R2, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: November 30, 2017Publication date: June 7, 2018Applicant: Genentech, Inc.Inventors: Snahel Patel, Gregory Hamilton, Guiling Zhao, Huifen Chen
-
Publication number: 20180153832Abstract: The present invention is directed to an aqueous gel composition containing a local anesthetic, a lubricating agent, and a preservative and methods of treating vulvovaginal pain, such as dyspareunia by topically administering said composition.Type: ApplicationFiled: January 22, 2018Publication date: June 7, 2018Inventors: Elias Reichel, Lauren Oshry